{"id":32719,"date":"2017-10-01T11:50:31","date_gmt":"2017-10-01T11:50:31","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=32719"},"modified":"2017-10-05T14:33:41","modified_gmt":"2017-10-05T14:33:41","slug":"dual-therapy-with-darunavirr-plus-lamivudine-as-first-line-art","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/32719","title":{"rendered":"Dual therapy with darunavir\/r plus lamivudine as first-line ART"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

Dual therapy using boosted darunavir plus lamivudine for first-line ART was compared to standard triple therapy (with added tenofovir DF) in a randomised open-label phase 4 study. <\/strong><\/p>\n

The ANDES study enrolled 145 treatment-naive participants in sites in Argentina. Interim viral efficacy results at 24-week results using <400 copies\/mL cut-off (presented as a late-breaking oral abstract at IAS 2017) were used to determine whether the study enrolled an additional 190 participants with primary endpoint of viral suppression <50 copies\/mL at week-48.<\/p>\n

Baseline characteristics included median age 30 (IQR: 25 to 39) years, 91% male. Median baseline CD4 and viral load were 383 (IQR: 286 to 562) cells\/mm3<\/sup> and 4.5 (4.0-5.0) log copies\/mL respectively, with 24% having viral load >100,000 copies\/mL.<\/p>\n

At week-24, viral suppression <400 copies\/mL was reports for 95% vs 97% participants in the dual vs triple therapy groups (difference: \u20132.5%; 95% CI: \u20137.9 to 2.9). Median CD4 increases were also similar: +206 vs +204 cell\/mm3<\/sup>, respectively.<\/p>\n

Although there were more discontinuations in the dual therapy arm (4 vs 1), the only case of virological failure was in the triple-therapy arm.<\/p>\n

Side effects were broadly similar, but GI side effects were more common in the triple therapy group (6% vs 12%).<\/p>\n

The second phase of this study in now enrolling to provide 48-week final data.<\/p>\n

Reference<\/p>\n

Cahn P et al. Dual therapy with darunavir\/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized. ANDES study. Late breaker oral abstract MOAB0106.
\nhttp:\/\/programme.ias2017.org\/Abstract\/Abstract\/5615 (abstract)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base Dual therapy using boosted darunavir plus lamivudine for first-line ART was compared to standard triple therapy (with added tenofovir DF) in a randomised open-label phase 4 study. The ANDES study enrolled 145 treatment-naive participants in sites …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[243],"class_list":["post-32719","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-ias-9-paris-2017"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=32719"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32719\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=32719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=32719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=32719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}